Clopidogrel Chemical Structure (Clopidogrel 1)
Clopidogrel
Product Images NDC 54458-888
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 54458-888). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by International Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 8 (Clopidogrel 10)
Eae (Clopidogrel 11)
This is a description of a medication package for Clopidogrel Tablets with Noc 5088810. The package contains 4 tablets of Clopidogrel with 75 mg of the active ingredient. The medication is stored in a child-resistant packaging that also includes a medication tracking card that can be pressed and pulled to open. The package has additional warning labels and instructions for use and storage. The package is sold by Walmart.*
Clopidogrel Tablets Usp 75 mg Bottle Label (Clopidogrel 12)
Clopidogrel is a prescription drug available in tablet form. Each film-coated tablet contains 97.875 mg of clopidogrel bisulfate USP equivalent to 75 mg of clopidogrel base. It is important to read the medication guide before use. The dosage information is included in the package insert. The bottle should be kept out of reach of children and should not be used if the safety seal under the cap is broken. The package features a child-resistant cap that should be tightly closed after use. The tablets should be stored in a controlled room temperature between 20°C to 25°C (68°F to 77°F). The product is manufactured by International Laboratories, LLC located in St. Petersburg, FL.*
Figure 1 (Clopidogrel 2)
Figure 2 (Clopidogrel 3)
This appears to be a chart showing the cumulative event rate of cardiovascular death, myocardial infarction, and stroke for patients using a placebo with aspirin and those using clopidogrel with aspirin, over a period of 9 months of follow-up. The percentage for each category is not clear due to the quality of the text. Other standard therapies were reportedly used as well.*
Figure3 (Clopidogrel 4)
Figure3_part2 (Clopidogrel 5)
Figure 4 (Clopidogrel 6)
The text seems to be presenting data about the effectiveness of a drug called Clopidogrel in reducing the risk of death in a study. The study involved a placebo group and a group of patients who received Clopidogrel. The percentage of deaths was lower in the Clopidogrel group (7.5%) compared to the placebo group (8.1%). The data also suggests that there was a 7% proportional risk reduction associated with the use of Clopidogrel. The study tracked patients for up to 28 days from randomization.*
Figure 5 (Clopidogrel 7)
The text describes the results of a study comparing the effectiveness of Placebo and Clopidogrel in reducing the risk of death, reinfarction or stroke before the discharge of a patient, within 28 days of randomization. Both groups had a similar number of events, with 10.1% in the Placebo group and 9.2% in the Clopidogrel group. However, the study found a proportional risk reduction of 9% to 9% in Clopidogrel compared to Placebo, which was statistically significant (p=0.002). The text also shows a graph of Days since randomization.*
Figure 6 (Clopidogrel 8)
Figure 7 (Clopidogrel 9)
The text shows a graph representing the cumulative event rate in percentages for fatal or non-fatal vascular events, comparing the drugs Aspirin and Clopidogrel. The months of follow-up are also displayed on the graph. The significance level is represented by "P=0.045".*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
